Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2024-10-28 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
第四届董事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixth meeting of the fourth board of directors of Jiangsu Senxuan Pharmaceutical Co., Ltd. It includes details about the meeting date, attendance, and voting results on the agenda, specifically the approval of the 2024 third quarter report. The document references the actual third quarter report being disclosed separately on the Beijing Stock Exchange information platform (announcement number 2024-057), indicating this document is not the report itself but an announcement of the board meeting resolutions. The document length is short (1087 characters) and primarily serves as a meeting resolution announcement rather than containing substantive financial data or the report itself. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2024-10-28 Chinese
第四届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the fifth meeting of the fourth board of directors of Jiangsu Senxuan Pharmaceutical Co., Ltd. It includes details about the meeting's convening, attendance, and voting results on specific agenda items. The agenda items reference other reports such as the 2024 semi-annual report and a special report on the use of raised funds, but these reports are not included in this document; instead, the document provides links or references to where these reports can be found. The document is short (1423 characters) and serves as an announcement of board meeting resolutions rather than the reports themselves. Therefore, it fits best into the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2024-08-26 Chinese
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "半年度报告" which translates to "Half-Year Report" or "Interim Report" for the period January 1, 2024 to June 30, 2024. It contains detailed financial data including income statement, balance sheet, cash flow, segment analysis, and operational review. The length is substantial (15,000 characters), and it includes comprehensive financial and operational information, not just an announcement or summary. It explicitly states it is a half-year report and includes actual financial statements and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-26 Chinese
2024年1-6月募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by Jiangsu Senxuan Pharmaceutical Co., Ltd. It includes specifics about the amount raised, usage of funds, changes in fund allocation, compliance with regulatory requirements, and approvals from board and shareholder meetings. The document references regulatory approvals, fund usage for projects and working capital, and includes financial figures and project feasibility analysis. It is a specialized report focusing on the status and use of raised capital, not a general annual or quarterly financial report, nor an earnings release or management discussion. The content aligns with a Capital/Financing Update, specifically a report on the status and use of raised funds, which fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed financial and project data, confirming it is the report itself, not just an announcement or certification.
2024-08-26 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" for the year 2024. It contains detailed financial data such as total assets, net profit, revenue, earnings per share, and other financial metrics for the half-year period. It also includes company business descriptions, shareholder information, and notes on asset pledges and restrictions. The document explicitly states it is a half-year report summary derived from the full half-year report and includes substantive financial data and analysis. The length is 4207 characters, which is sufficient for a summary but still contains actual financial data, not just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-26 Chinese
第四届监事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the convening and attendance of the Supervisory Board meeting, the approval of the 2024 semi-annual report and its summary, and the approval of a special report on the use of raised funds for the first half of 2024. The document references the actual reports being disclosed on the Beijing Stock Exchange information platform with specific announcement numbers, indicating that this document itself is not the report but an announcement of the meeting resolutions approving those reports. The document length is short (1233 characters), and it does not contain substantive financial data or detailed report content, only the meeting resolutions and voting results. Therefore, it fits the category of Regulatory Filings (RNS) as a formal announcement of meeting resolutions and approvals rather than the reports themselves or a voting results declaration (DVA) since it is from the Supervisory Board, not a shareholder meeting. Confidence is high due to clear meeting and resolution context and references to external report disclosures.
2024-08-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.